60 Degrees Pharmaceuticals Inc.
SXTP Healthcare Biotechnology
60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS grew 82.0% and free cash flow fell 54.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SXTP
60 Degrees Pharmaceuticals Inc. (SXTP) P/E ratio
60 Degrees Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 13.7× (July 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 1.0× | — |
| 14 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. | n/m |
| EOCN Eocene Ltd. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)